Готові списки джерел за темами / Newly diagnosed type 2 diabete

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Добірка наукової літератури з теми "Newly diagnosed type 2 diabete"

Автор: Grafiati

Опубліковано: 11 березня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Newly diagnosed type 2 diabete".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Newly diagnosed type 2 diabete"

Raju Taklikar, Anupama. "Prevalence of Diabetic Retinopathy in Newly Diagnosed Cases of Type 2 Diabetes Mellitus." Ophthalmology and Allied Sciences 6, no. 1 (April 1, 2020): 9–11. http://dx.doi.org/10.21088/oas.2454.7816.6120.1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

M. Normatova, Nargiza. "PREVALENCE OF DIABETIC RETINOPATHY IN NEWLY DIAGNOSED PEOPLE WITH TYPE 2 DIABETES IN UZBEKISTAN." International Journal of Psychosocial Rehabilitation 24, no. 02 (February 28, 2020): 2254–57. http://dx.doi.org/10.37200/ijpr/v24i4/pr201335.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Smith, S. M. "Newly diagnosed type 2 diabetes mellitus." BMJ 326, no. 7403 (June 19, 2003): 1371. http://dx.doi.org/10.1136/bmj.326.7403.1371.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hong, Li, Ruan Yu, and Li Y-Hua. "Depression in newly diagnosed type 2 diabetes." International Journal of Diabetes in Developing Countries 30, no. 2 (2010): 102. http://dx.doi.org/10.4103/0973-3930.62601.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Harrison, Lindsay B., Beverley Adams-Huet, Xilong Li, Philip Raskin, and Ildiko Lingvay. "Intensive Therapy in Newly Diagnosed Type 2 Diabetes." Journal of Investigative Medicine 62, no. 4 (April 1, 2014): 676–86. http://dx.doi.org/10.2310/jim.0000000000000068.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Al-Zuabi, Homoud, Yaqoub Al-Tammar, Reem Al-Moataz, Khalid Al-Sabti, Vivek B. Wani, Fahad Hamama, Hanan Mohammad, and Mai H. Al-Suwayan. "Retinopathy in Newly Diagnosed Type 2 Diabetes mellitus." Medical Principles and Practice 14, no. 5 (2005): 293–96. http://dx.doi.org/10.1159/000086925.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Sakuta, Suzuki, Yasuda, and Ito. "Plasma Folate Levels in Men with Type 2 Diabetes." International Journal for Vitamin and Nutrition Research 75, no. 5 (September 1, 2005): 307–11. http://dx.doi.org/10.1024/0300-9831.75.5.307.

Повний текст джерела

Анотація:

Limited data suggest that folate levels are higher in patients with type 2 diabetes than in subjects with normal glucose tolerance (NGT). We compared the fasting plasma folate, glucose (FPG), body mass index (BMI), and supplementary vitamin use among male subjects with NGT, those with impaired glucose tolerance (IGT), those with newly diagnosed type 2 diabetes, and those with previously diagnosed type 2 diabetes. Plasma folate of patients with newly diagnosed diabetes and that of patients with previously diagnosed diabetes was significantly higher than that of NGT subjects (p < 0.001). Prevalence of vitamin use was lower in newly diagnosed or previously diagnosed diabetic patients compared with non-diabetic subjects. Self-rated vegetable intake was similar among the four groups. FPG, BMI, triglycerides, and systolic blood pressure correlated with plasma folate levels independently of lifestyle factors studied. These results suggest that plasma folate levels are elevated in male diabetic patients independently of health-conscious behavior that is recommended for diabetic people.

Стилі APA, Harvard, Vancouver, ISO та ін.

Joob, Beuy, and Viroj Wiwanitkit. "Raised liver enzymes in newly diagnosed type 2 diabetes." Indian Journal of Endocrinology and Metabolism 17, no. 3 (2013): 535. http://dx.doi.org/10.4103/2230-8210.111688.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Saligram, Shreyas, Elizabeth Williams, and Michael Masding. "Raised Liver Enzymes in Newly Diagnosed Type 2 Diabetes." American Journal of Gastroenterology 105 (October 2010): S96—S97. http://dx.doi.org/10.14309/00000434-201010001-00258.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bentley-Lewis, R. "Nature Versus Nurture in Newly Diagnosed Type 2 Diabetes." Science Translational Medicine 3, no. 64 (January 5, 2011): 64ec2. http://dx.doi.org/10.1126/scitranslmed.3002072.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Newly diagnosed type 2 diabete"

BONETTI, Sara. "Influence of genetic factors in newly diagnosed type 2 diabeticpatients: the TCF7L2 and GENETIC LOAD studies." Doctoral thesis, Università degli Studi di Verona, 2010. http://hdl.handle.net/11562/343536.

Повний текст джерела

Анотація:

Introduzione. Negli ultimi anni sono stati individuati molti nuovi polimorfismi (SNP, Single Nucleotide Polymorphisms) associati allo sviluppo di diabete di tipo 2 (T2DM), soprattutto grazie all’avvento di nuove tecniche di genotipizzazione su larga scala, GWAS (Genome Wide Association Scan). Ogni SNP però contribuisce da solo in modo marginale al rischio di sviluppare la malattia e spesso è poco chiara la funzione biologica di queste varianti geniche nella regolazione dell’omeostasi del glucosio. Tra questi polimorfismi, la variante intronica rs7903146 del gene TCF7L2 (Transcription Factor 7 Like 2) è al momento il più forte fattore di rischio per il diabete di tipo 2 (O.R.= 1.37). Scopo dello studio. Chiarire l’effetto di diversi loci associati allo sviluppo di T2DM su fenotipi clinici e patofisiologici (funzione beta-cellulare e sensibilità insulinica) in pazienti con T2DM neo-diagnosticato. Metodi. Abbiamo analizzato 464 pazienti di discendenza italiana con T2DM neodiagnosticato, anti-GAD negativi. La caratterizzazione clinica standard è stata effettuata mediante metodi classici. La funzione beta-cellulare è stata valutata applicando un modello matematico alle curve di glucosio e di C-peptide derivanti da prelievi eseguiti durante OGTT, ed è differenziabile in due componenti: prima fase di secrezione insulinica o controllo derivativo, rappresentato dalla quantità di insulina secreta in risposta all’incremento unitario della concentrazione di glucosio, e la seconda fase di secrezione o controllo proporzionale, rappresentato come la velocità di secrezione insulinica a concentrazioni crescenti di glucosio (5.5, 8.0, 11.0, 15.0 and 20.0 mM). La misura della sensibilità insulinica deriva dalla quantità di glucosio infuso che viene metabolizzato negli ultimi 60 minuti del clamp euglicemica, tale valore è detto M. Sono stati genotipizzati i seguenti SNP, già visti essere associati allo sviluppo di T2DM: rs7901695 (TCF7L2), rs7903146 (TCF7L2), rs11196205 (TCF7L2), rs12255372 (TCF7L2), rs679931 (CACNA1E), rs1801282 (PPARG), rs1044498 (ENPP1), rs10946398 (CDKAL1), rs1111875 (HHEX/IDE) rs10010131 (WFS1), rs4430796 (TCF2), rs4402960 (IGF2BP2). Risultati. TCF7L2. Gli alleli di rischio di 3 su 4 polimorfismi di TCF7L2 (rs7901695, rs7903146, rs11196205) sono associati a più alti valori plasmatici di glucosio a digiuno (p<0.001, p<0.03 e p<0.01 rispettivamente). Gli allele di rischio dei primi due SNP (rs7901695 e rs7903146) sono associati ad un aumento del controllo proporzionale della funzione beta cellulare (p<0.02 e p<0.03 rispettivamente). Tramite l’analisi degli aplotipi sono stati individuati 4 aplotipi rappresentati nella popolazione in esame e due di questi (haplo4, frequenza: 0.038 e haplo9, frequenza: 0.086) hanno un forte impatto sulla funzione beta-cellulare. Altre varianti geniche. Nessuno dei rimanenti 8 polimorfismi (rs679931, rs1801282, rs1044498, rs10946398, rs1111875, rs10010131, rs4430796, rs4402960) ha mostrato associazione indipendente con alterazioni della funzione beta-cellulare o della sensibilità insulinica. Abbiamo calcolato uno score genetico di queste varianti sommando il numero di alleli di rischio presenti in ogni paziente (escludendo TCF7L2). I pazienti sono stati divisi in tre gruppi: portatori di un numero di alleli di rischio ≤ 6 (gruppo A, n=76), pazienti con un numero di alleli di rischio compresa tra 7 e 9 (gruppo B, n=226) e soggetti con un numero di alleli di rischio ≥ 10 (gruppo C, n=69). Il controllo proporzionale della funzione beta cellulare risultava alterato in modo statisticamente significativo (p=0.05) nel gruppo C rispetto agli altri due gruppi. Maggiore è il numero di alleli di rischio associato a T2DM, peggiore è la funzione beta-cellulare. Conclusioni. Questi dati mostrano come diverse varianti geniche giocano un ruolo significativo nel determinare il fenotipo patofisiologico dei pazienti con T2DM neo-diagnosticato, influenzando soprattutto la funzione beta-cellulare. Perciò, la valutazione dei genotipi di rischio per il T2DM potrebbe tornare utile per scopi diagnostici, prognostici e terapeutici in pazienti con T2DM neodiagnosticato.
Background. Genome wide association studies (GWAS) have played a primary role in demonstrating that genetic variation in a number of loci, as assessed by single nucleotide polymorphisms (SNPs), affects the risk of type 2 diabetes mellitus (T2DM). Among these, rs7903146, an intronic variant of the TCF7L2 (Transcription Factor 7 Like 2) gene, is possibly the strongest known genetic risk factor for T2DM (O.R.=1.37). Each risk variant, however, per se contributes quantitatively little to the overall risk and is often of questionable biological significance in affecting the determinants of glucose regulation. Aim(s). To elucidate the effects of several T2DM risk genetic loci on clinical and pathophysiological (beta-cell function and insulin sensitivity) phenotypes of patients with newly diagnosed T2DM. Methods. We studied 464 patients of Italian ancestry with newly diagnosed, GAD-antibody negative, type 2 diabetes mellitus. Standard clinical phenotyping was carried out by classical methods. Beta-cell function and insulin sensitivity were assessed by mathematical modeling of glucose and C-peptide curves during a 240’ frequently sampled OGTT and by euglycemic insulin clamp, respectively. Beta-cell function is described as the sum of two components: i. first phase of insulin secretion or derivative control (DC), presented as the pulse secretory response to a unit rate of change in glucose concentration; ii. second phase of insulin secretion or proportional control (PC), presented as the insulin secretion rate at glucose concentrations of 5.5, 8.0, 11.0, 15.0 and 20.0 mM, respectively. Insulin sensitivity is presented as the amount of glucose infused which is metabolized in the last 60’ of the euglycemic clamp (M value). The following SNPs (related gene in brackets), already known to be risk loci of T2DM, were genotyped: rs7901695 (TCF7L2), rs7903146 (TCF7L2), rs11196205 (TCF7L2), rs12255372 (TCF7L2), rs679931 (CACNA1E), rs1801282 (PPARG), rs1044498 (ENPP1), rs10946398 (CDKAL1), rs1111875 (HHEX/IDE) rs10010131 (WFS1), rs4430796 (TCF2), rs4402960 (IGF2BP2). Results. TCF7L2. The risk alleles of 3 (rs7901695, rs7903146, rs11196205) out of 4 TCF7L2 SNPs were associated with higher fasting plasma glucose (p<0.01, p<0.03 and p<0.01 respectively). The risk alleles of the first two SNPs (rs7901695, rs7903146) were associated to a decrease in the proportional control of beta-cell function (p<0.02 and p<0.03 respectively). Four TCF7L2 haplotypes were detected, two of which (haplo4, frequency: 0.038; and haplo9, frequency: 0.086) had a strong impact on beta-cell function. Haplo4 was associated with the lowest proportional control of beta-cell function while haplo9 showed the highest. Other genetic variants. None of the 8 remaining SNPs (rs679931, rs1801282, rs1044498, rs10946398, rs1111875, rs10010131, rs4430796, rs4402960) showed any significant independent association with insulin sensitivity or beta-cell function. We computed a genetic risk score of this variants, by summing the number of the T2DM risk alleles present in each patient (excluding TCF7L2). The patients were divided into three groups: 6 or less risk alleles (group A, n=76), 7-9 risk alleles (group B, n=226), 10 or more risk alleles (group C, n=69). The porportional control of beta-cell function was significantly impaired (P=0.05) in group C than in the other two groups, i.e. the higher the number of T2DM risk variants the lower beta cell function. Conclusions. These data show that several genetic variants play a significant role in determining the pathophysiological phenotype of patients with newly diagnosed type 2 diabetes, with most of the influence exerted on beta-cell function. Thus, assessment of T2DM risk genotype may turn to be useful for diagnostic, prognostic and therapeutic purposes in patients with newly diagnosed T2DM.

Стилі APA, Harvard, Vancouver, ISO та ін.

Engdahl, Ylva. "HOPE Platform Digital Toolfor Type 2 Diabetes : Supporting Newly Diagnosed Patients in Self-Care." Thesis, KTH, Medicinteknik och hälsosystem, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-297535.

Повний текст джерела

Анотація:

Type 2 diabetes is a chronic disease whose incidence has increased with more than 200% during the past 20 years. The increasing number of type 2 diabetes patients could result in more patients suffering from lower quality of life and life threatening complications. Furthermore, the growing need of care will increase the load on healthcare. To counteract this effect, digital tools could be used to put more care responsibility on the patient. The aim of this project was to find and implement the relevant features for a digital type 2 diabetes tool for newly diagnosed patients. The final goal was to encourage self-care, reduce anxiety and thus improve quality of life, while decreasing the risk of complications. The research process of this project consisted of five phases: literature study (to find relevant features and their clinical evidence), interviews (to find the desires of patients and practitioners), data analysis (to prioritise features), development of the features and evaluation of the tool. The results showed that important features were documentation of blood glucose measurements, patient education, data transfer, communication and care plan overview, but even more importantwas the possibility to individualise the tool for different patients. The evaluation indicated that a clear care plan overview that was easy to understand could help the patient prioritise care activities. Furthermore, patients could be encouraged by reminders, seeing improvements and having continuous communication with healthcare. It was found that for positive clinical outcomes, high usability is essential. To reach patient acceptance the tool must be relevant and easy to use. It must also give valuable output, such as decision support for self-care or new knowledge. To reach practitioner acceptance the tool should be based on evidence based methods and integrate well with existing systems. Finally it was concluded that the knowledge and technology needed to build a successful tool is already present, they only need to be put together and formulated in a way which is understandable and useful for both patients, caregivers and developers.
Diabetes typ 2 är en kronisk sjukdom vars incidens har ökat med mer än 200% de senaste 20 åren. Det stigande antalet patienter med diabetes typ 2 kan leda till att fler patienter blir lidande av lägre livskvalitet och livshotande komplikationer. Dessutom ökar det stigande vårdbehovet belastningen på vården. För att motverka denna effekt kan digitala verktyg utvecklas så att mer ansvar kan läggas på patienten. Syftet med detta projekt var att hitta och implementera relevanta funktioner för ett digitalt verktyg för nydiagnostiserade patienter med diabetes typ 2. Målet var att uppmuntra egenvård, minska oro och därmed öka livskvaliteten samt minska risken för komplikationer. Projektets forskningsprocess bestod av fem faser: litteraturstudie (finna relevanta funktioner och deras evidens), intervjuer (kartlägga krav från patienter och vårdgivare), dataanalys (prioritera funktioner), utveckling av funktioner i HOPE platform och slutligen utvärdering av verktyget i HOPE platform. Resultaten visade att dokumentation av blodglukosmätningar, patientutbildning, dataöverföring, kommunikation och vårdplansöversikt var viktiga funktioner, men ännu viktigare var möjligheten att individanpassa verktyget för varje patient. Utvärderingen indikerade att en tydlig vårdplansöversikt som är enkel att förstå hjälper patienten att prioritera de viktigaste vårdaktiviteterna. Vidare kan patienter motiveras av påminnelser, att se förbättring och att ha kontinuerlig kontakt med vården. Det konstaterades att hög användbarhet är nödvändig för att uppnå positiva kliniska effekter. För att nå acceptans hos patienterna måste verktyget vara relevant, enkelt att använda och ge något värdefull tillbaka, så som beslutsstöd för egenvård eller ny kunskap. För att nå acceptans hos vårdgivarna bör verktyget baseras på evidensbaserade metoder och vara kompatibelt med nuvarande system. Slutligen drogs slutsatsen att kunskapen och tekniken för att skapa ett lyckat verktyg redan finns, men att kraven måste sammanställas och formuleras på ett sätt som är förståeligt och användbart för både patienter, vårdgivare och utvecklare.

Стилі APA, Harvard, Vancouver, ISO та ін.

Korsah, Kwadwo Ameyaw. "Coping strategies of newly diagnosed patients with type two diabetes mellitus at a hospital in Ghana." Thesis, De Montfort University, 2015. http://hdl.handle.net/2086/11104.

Повний текст джерела

Анотація:

Published research on diabetes in Ghana is quite limited and relates mainly to incidence and prevalence of the disease with little research on the patients experiences of coping with the diabetes. It is estimated that diabetes affects 6.3% of the Ghanaian population with type 2 diabetes accounting for 90-95% of all cases of diabetes. In Ghana, individuals diagnosed with type 2 diabetes mellitus are confronted with difficulties including the high cost of treatment of the condition, stigmatization, and interruptions to normal physiological processes. In addition, the patients experience, limited clinic accessibility, inadequate drug availability, inadequate numbers of trained staff, as well as limited availability of equipment needed for adequate care of the condition. The review of literature for this current thesis also showed that none of the studies on coping were undertaken in Ghana, but were conducted in the western world where socio-cultural factors are quite diverse from the Ghanaian situation. In the light of the challenges facing diabetic patients as well as the gap observed in literature, the study set out to explore the coping strategies of patients with type 2 diabetes mellitus at a hospital in Ghana. A hermeneutic phenomenological approach to qualitative research was utilized. Twenty seven (27) in-depth interviews carried out with newly diagnosed patients with type 2 diabetes, between August and October 2009 at a hospital in Ghana. Interviews were conducted in the local Ghanaian Twi language and English. Participants who could not speak English were interviewed in Twi language and later translated into English by the researcher. Data analysis used Creswell (1998) approach to qualitative data analysis, which provided a rich description of the essential structures of the phenomenon under study. The study identified patients’ perceptions as to the causes of diabetes mellitus, the social meanings attributed to diabetes (with particular attention paid to the language by Ghanaian people to describe disease condition), and subsequently reactions and resolutions to diagnosis. Patients discussed treatment options, while at the same time remaining hopeful of finding a cure. All patients had a firm spiritual belief system that underpinned their understanding of the causation and treatment of their illness. This combined with various degrees of understanding and acceptance of western explanations of illness influenced the coping strategies employed by patients, which variously reported as positive, negative, and alternative strategies. The study establishes a platform upon which health providers can develop educational programmes for diabetic patients in Ghana, which will address misconceptions about diabetes mellitus in Ghana and the importance of programmes of care, which take account of and build upon the cultural context of ‘being Ghanaian’. Diabetes, at least for Ghanaian patients is more than a biomedical disease. In this sense a biomedical framework in and of itself will not enable healthcare providers to effectively manage this chronic disease in the Ghanaian population, but through the inclusion of an understanding of their spiritual beliefs, healthcare providers can understand the realities of what it is like for Ghanaian diabetes patients to live with diabetes. It is argued that a stronger collaboration and integration between traditional healthcare systems and orthodox healthcare systems will provide the optimum opportunity to maximize patient care in Ghana. Future research should concentrate on better understanding how lay knowledge and health related attitudes, beliefs and behaviours are associated with diabetes in Ghana.

Стилі APA, Harvard, Vancouver, ISO та ін.

Kawamura, Taichi. "Influence of comorbidities on the implementation of the fundus examination in patients with newly diagnosed type 2 diabetes." Kyoto University, 2018. http://hdl.handle.net/2433/232479.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Jones, Candice N. "Examining Racial Differences in Knowledge and Attitudes of Diabetes Management in Newly Diagnosed Type 2 Diabetes Patients." University of Cincinnati / OhioLINK, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1313773398.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ford, Teri. "Motivation to self-care in newly diagnosed type 2 diabetes mellitus : a longitudinal study of the predictors." Thesis, Staffordshire University, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.431501.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Guzder, Rustom. "A community study of newly diagnosed type 2 diabetes : incidence, cardiovascular risk and early mortality : the Poole Diabetes Study." Thesis, University of Southampton, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.440622.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Sandholm, Mathilda, and Veronika Erdner. "När förändringens vind blåser : Patienters upplevelser av att få diagnosen diabetes typ 2. En litteraturstudie." Thesis, Ersta Sköndal högskola, Institutionen för vårdvetenskap, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:esh:diva-1575.

Повний текст джерела

Анотація:

Bakgrund: Diabetes typ 2 utgör den vanligaste diabetesformen, och cirka 4 % av Sveriges befolkning uppskattades ha diabetes 2010, varav nästan 90 % av dessa utgjordes av diabetes typ 2. Sjuksköterskan har en viktig roll i att stödja och vägleda patienten utifrån dennes upplevelser och behov. Syfte: Att beskriva hur vuxna patienter upplever att diagnostiseras med diabetes typ 2. Metod: Denna studie är en litteraturstudie baserad på tidigare forskning kring diabetes typ 2, och kommer att fokusera på fenomen relaterat till patienters upplevelser av att få en diagnos. Författarna identifierade sex teman: Upplevelser och känslomässiga reaktioner vid diagnos, Information och kunskap, Lära sig leva med diabetes, Att förneka sin sjukdom, Eget ansvar och egenvård samt Syn på framtiden. Teoretisk referensram: Som teoretiskreferensram valdes Afaf Meleis' Transitionsteori som bygger på tanken om att människor går igenom transitioner i livet av olika art. Resultat: Resultaten visade att deltagarna upplevde att få en diagnos som diabetes typ 2 på olika sätt beroende på hur deras liv sett ut tiden innan diagnos. Det framkom också att kunskapen kring diabetes varierade och att deltagarna hade olika behov av information och stöd vid tillfälle för diagnos. Diskussion: Att få en diagnos som diabetes typ 2 kan upplevas olika och vi har sett att det finns vissa faktorer som kan påverka upplevelsen. Faktorer som vi menar kan ha en inverkan är: den information och det stöd som ges vid diagnos, samt vilket bagage och vilken förförståelse personen i fråga har sedan tidigare.
Background: Type 2 Diabetes is the most common form of diabetes, and approximately 4 % of Sweden's population was estimated to have diabetes in 2010, and almost 90 % of these consisted of type 2 diabetes. The nurse has an important role in supporting and guiding the patient based on his experiences and needs. Aim: To describe how adult patients experience of being diagnosed with diabetes type two. Method: This study is a literature review based on previous research on type 2 diabetes, and the focus will be on the phenomenon related to patient experiences of being diagnosed with type 2 diabetes. The authors identified six themes: Experiences and emotional reactions at diagnosis, Information and knowledge, Learning to live with diabetes, To deny their illness, Personal responsibility and self-care and views of the future. Theoretical framework: The theoretical framework that was chosen for this study was Afaf Meleis' Transition Theory, which is based on the idea that people go through different transitions in life. Results: The results showed that patients experienced diagnosis of type 2 diabetes in different ways, depending on what their life looked like at the time before diagnosis. Findings also demonstrated that knowledge about diabetes varied among participants, and that they had different needs for information and support at the time of diagnosis. Discussion: To receive a diagnosis like type 2 diabetes, can be experienced in different ways, and we have seen that certain factors can have an impact on the experience. These factors that we have identified are: information and support at the time of diagnosis, and the baggage and pre-understanding the person have before diagnosis.

Стилі APA, Harvard, Vancouver, ISO та ін.

Adarkwah-Yiadom, Charles Christian [Verfasser]. "Cost-effectiveness of ACE inhibitors in newly diagnosed type 2 diabetic patients in Germany / Charles Christian Adarkwah-Yiadom." Köln : Deutsche Zentralbibliothek für Medizin, 2011. http://d-nb.info/101002955X/34.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Mitsui, Rie. "Characteristics of Insulin Secretory Capacity and Insulin Sensitivity in Impaired Fasting Glucose and Newly Diagnosed Type 2 Diabetes in Japanese." Kyoto University, 2012. http://hdl.handle.net/2433/158053.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Книги з теми "Newly diagnosed type 2 diabete"

Type 2 diabetes: An essential guide for the newly diagnosed. 2nd ed. New York: Marlowe & Co., 2007.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

The first year--type 2 diabetes: An essential guide for the newly diagnosed. New York: Marlowe and Co., 2001.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Noble, Steven C. Diabetic Diet Cookbook for the Newly Diagnosed: 1001 Recipes to Manage Type 2 Diabetes. Independently Published, 2021.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Becker, Gretchen, and Allison Goldfine. First Year : Type 2 Diabetes: An Essential Guide for the Newly Diagnosed. Hachette Books, 2015.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Becker, Gretchen, and Allison Goldfine. First Year : Type 2 Diabetes: An Essential Guide for the Newly Diagnosed. Hachette Books, 2009.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

The first year: type 2 diabetes: An essential guide for the newly diagnosed. 2015.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Big Type 2 Diabetes Cookbook: Simple and Fast Diabetic Friendly Recipes for the Newly Diagnosed. Independently Published, 2022.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Becker, Gretchen. The First Year Type 2 Diabetes: An Essential Guide for the Newly Diagnosed. Health Text Audio / STI, 2006.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Becker, Gretchen. The First Year Type 2 Diabetes: An Essential Guide for the Newly Diagnosed. Marlowe & Company, 2001.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Aucter, Royce. 28-Day Meal Plan for the Newly Diagnosed for Type 2 Diabetes: Diabetic Cookbook for Men. Independently Published, 2020.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Частини книг з теми "Newly diagnosed type 2 diabete"

Miller, Joshua D. "Evaluation and Management of the Newly Diagnosed Patient with Type-2 Diabetes." In A Case-Based Guide to Clinical Endocrinology, 347–57. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2059-4_42.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Lamster, Ira B., Nurit Bittner, and Daniel Lorber. "Case 6: Prosthodontic treatment for the newly diagnosed patient with type 2 diabetes mellitus." In Diabetes Mellitus and Oral Health, 237–46. Hoboken, NJ, USA: John Wiley & Sons, Inc, 2014. http://dx.doi.org/10.1002/9781118887837.ch15.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Saleh Mshelia, Dahiru, Sani Adamu, and Rebecca Mtaku Gali. "Oral Glucose Tolerance Test (OGTT): Undeniably the First Choice Investigation of Dysglycaemia, Reproducibility can be Improved." In Type 2 Diabetes - From Pathophysiology to Cyber Systems. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96549.

Повний текст джерела

Анотація:

Type 2 diabetes mellitus accounts for ≈90–95% of those with diabetes, about 50% of those with type 2 diabetes are unaware and it can remain undiagnosed for up to 12 years, ≥25% of people have evidence of microvascular complications at diagnosis. The consequences of diabetes can be reduced by screening and early interventions. Urinalysis as a screening test is limited by its low sensitivity ranging from 21% and 64%, though has high specificity (>98%), it has a place where no other procedure is available. Fasting plasma glucose though recommended as a universal screening and diagnostic test for diabetes mellitus, a changed in the diagnostic criteria was made when this did not give corresponding hyperglycaemic impact compared to the OGTT results, bringing a complex and variable effect on the prevalence of diabetes and on subjects diagnosed. To date the searching to finding the corresponding FPG to what is normal or IGT is still ongoing. FPG testing poorly identify early signs of dysglycaemia. This is due to the difficulty ensuring compliance with instructions about fasting, FPG represents glucose handling during the moment of fasting period only and is affected easily by short-term lifestyle changes, FPG has diurnal variation, higher in the morning than in the afternoon, these may cause serious misclassifications. OGTT do indicates the pathophysiology responsible for diabetes better as it provides information on what happens in the postprandial state when the functional capacity of pancreatic β-cell is crucial. It accurately detects changes in post-prandial glycaemia that tend to precede changes in fasting glucose. OGTT is the gold standard for the diagnosis of GDM and the only means of identifying people with IGT and WHO placed emphasis on the OGTT as the “gold standard”, in diagnosis of dysglycaemia. Reproducibility can be improved remarkably when patient preparation, a forvarable atmosphere during the procedure, standardized sampling protocol, sample handling, and analysis are given high attention. Measurement of A1c equals the assessment of hundreds of FPG levels and also captures postprandial glucose peaks. Regrettably, it has been shown that 44% of people with newly diagnosed diabetes with OGTT had A1c <6.0% and that a stronger correlations with plasma glucose is better in subjects with known diabetes, but not in the general population. A1C values just above the upper limits of normal require OGTT to be correctly interpreted; it is not available in many part of the world. Finally, A1c can not diagnose IFG and IGT to disclose high-risk subjects for diabetes. In conclusion an OGTT is undeniably the best test in investigation of dysglycaemia, either with the intention of testing for pre-diabetes, type 2 diabetes, or for gestational diabetes mellitus.

Стилі APA, Harvard, Vancouver, ISO та ін.

"Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents." In Pediatric Clinical Practice Guidelines & Policies, 21st Ed, 175–96. American Academy of Pediatrics, 2021. http://dx.doi.org/10.1542/9781610025034-part01-management.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

"Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents." In Pediatric Clinical Practice Guidelines & Policies, 175–96. 22nd ed. American Academy of Pediatrics, 2022. http://dx.doi.org/10.1542/9781610026086-part01-08.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Silink, M. "Diabetic ketoacidosis in childhood and adolescence." In Oxford Textbook of Endocrinology and Diabetes, 1888–94. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235292.003.1473.

Повний текст джерела

Анотація:

Diabetic ketoacidosis (DKA) may occur at the time of diagnosis of diabetes, or at any time subsequently. It is the cause of very significant morbidity and remains the most common cause of death in childhood and adolescent diabetes (1–3). For a discussion of DKA in adults, see Chapter 13.4.10.1. Type 1 diabetes occurs in childhood (see Chapter 13.4.7) with an incidence that varies from more than 40 per year per 1 00 000 children under the age of 15 years old (in Finland), to less than 1 per 1 00 000 (in Asia). The mean age at diagnosis is usually 10–12 years old, although, in a number of countries, this seems to be declining. The younger the child is at diagnosis, the more aggressive the autoimmune-mediated destruction of the pancreatic β‎ cell, and the more rapid the progression to complete insulin dependence (see Chapter 13.2.3). Children are thus more liable to DKA than adults. Furthermore, children experience more viral infections than do adults, and the metabolic stresses associated with these infections increase their risk of developing DKA. DKA has traditionally been considered to occur only in type 1 diabetes, but is now being reported in at least 25% of (usually obese) adolescents with newly diagnosed type 2 diabetes, especially when there are associated stress factors, such as infection (4, 5). Although the vast majority of diabetes in childhood and adolescence is type 1 diabetes, there has been a worldwide trend to the earlier development of type 2 diabetes in association with the overweight and obesity epidemic, especially in certain at-risk ethnic groups, e.g. Asians, African Americans, Hispanic Americans; see Chapter 13.4.3.1. The treatment of DKA in these patients is the same as for those with type 1 diabetes; however, the subsequent course of the treatment usually differs, and most patients are able to stop insulin and be treated with oral hypoglycaemic agents, weight reduction, exercise, and an appropriate food plan.

Стилі APA, Harvard, Vancouver, ISO та ін.

Kirnap, NG, G. Gursoy, O. Esbah, Y. Acar, and B. Demirbas. "The Relationship between Plasma Omentin Levels and Insulin Resistance in Newly Diagnosed Type 2 Diabetic Patients." In The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego, P1–497—P1–497. Endocrine Society, 2010. http://dx.doi.org/10.1210/endo-meetings.2010.part1.p10.p1-497.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Choi, Moon Chan, Yun Jung Lee, Sang Ouk Chin, Sang Youl Rhee, Suk Chon, You Cheol Hwang, In Kyung Jeong, et al. "Biochemical, Lifestyle and Psychosocial Factor Characteristics of Newly Diagnosed Type 2 Diabetics: Baseline Data from the Korea National Diabetes Program Cohort Study." In CLINICAL - Miscellaneous Topics in Diabetes, P1–525—P1–525. The Endocrine Society, 2011. http://dx.doi.org/10.1210/endo-meetings.2011.part2.p10.p1-525.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ahmad, Qazi Najeeb. "Determining the Levels of Glycated Hemoglobin, Serum Calcium, Magnesium, Phosphate, Uric Acid and Microalbuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus." In Recent Developments in Medicine and Medical Research Vol. 11, 156–61. Book Publisher International (a part of SCIENCEDOMAIN International), 2021. http://dx.doi.org/10.9734/bpi/rdmmr/v11/13929d.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Newly diagnosed type 2 diabete"

Dugic, A., M. Kryk, C. Braig, J. Kothmann, S. Petermann, and S. Mühldorfer. "Severe asymptomatic hypertriglyceridemia promoted by uncontrolled fructose ingestion in newly diagnosed type 2 diabetes treated with plasmapheresis." In Diabetes Kongress 2021 – 55. Jahrestagung der DDG. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1727340.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bongaerts, B., B. Kollhorst, O. Kuss, I. Pigeot, and W. Rathmann. "Glucose-lowering drug prescriptions in patients with newly diagnosed type 2 diabetes: statutory health insurance data from 2012 – 2016." In Diabetes Kongress 2019 – 54. Jahrestagung der DDG. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1688177.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bongaerts, B., W. Rathmann, K. Strassburger, O. Kuss, K. Müssig, V. Burkart, J. Szendroedi, et al. "Genetic variants of the glucose transporter gene SLC2A2 modify the glycemic response to metformin monotherapy in newly diagnosed type 2 diabetes." In Diabetes Kongress 2018 – 53. Jahrestagung der DDG. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1641801.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Xuan-Hui Goh, Joanna, Loh Teng-Hern Tan, Jodi Woan-Fei Law, Vengadesh Letchumanan, Bey-Hing Goh, and Learn-Han Lee. "IDDF2022-ABS-0231 The effect of probiotic supplementation in newly diagnosed type-1 diabetes mellitus patient: a systematic review of randomized controlled trials." In Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, 2–4 September 2022. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2022. http://dx.doi.org/10.1136/gutjnl-2022-iddf.73.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Mohamed, AM, J. Romli, K. Ismail, and K. Winkley. "P37 Barriers to and facilitators of effective diabetes self-management among people newly diagnosed with type 2 diabetes mellitus (t2dm): a qualitative study from malaysia." In Society for Social Medicine, 61st Annual Scientific Meeting, University of Manchester, 5–8 September 2017. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/jech-2017-ssmabstracts.139.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Minhas, Dimple, Anbezhil Subbarayan, and Prem Sundaram. "627 Are greater numbers of children with newly diagnosed type 2 diabetes mellitus a further example of collateral damage from the COVID-19 pandemic?" In Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference–Online, 15 June 2021–17 June 2021. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2021. http://dx.doi.org/10.1136/archdischild-2021-rcpch.109.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Newly diagnosed type 2 diabete"

Wu, Xin. The efficacy and safety of anti-CD20 antibody treatments in relapsing multiple sclerosis: a systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0075.

Повний текст джерела

Анотація:

Review question / Objective: The objectives of this systematic review were to evaluate the efficacy and safety of the three existing anti-CD20 antibodies for the treatment of relapsing multiple sclerosis and to aid clinicians in choosing medications. Eligibility criteria: We set the inclusion criteria as follows: (1) study type: RCT; (2) language restriction: only available in English; (3) participants: patients ≥18 years of age diagnosed with relapsing MS, whether with a relapsing–remitting course or a secondary progressive course; (4) intervention: anti-CD20 antibody treatments including ocrelizumab, ofatumumab, rituximab, and corresponding control including placebo and active treatments; (5) outcomes: clinical outcomes including annualized rate of relapse (ARR), the number of patients free of relapse, and the number of patients with confirmed disease progression (CDP); magnetic resonance imaging(MRI) outcomes including gadolinium-enhancing lesion change in T1, change in the volume of lesions on T2, the number of patients with no new or newly enlarged lesions in T2 and the brain volume change (BVC); safety outcomes including adverse events (AEs) and serious adverse events (SAEs). Included RCTs were not requested to supply all the outcomes mentioned above. We set the exclusion criteria as follows: (1) study type: retrospective studies, cohort studies, case reviews and case reports; (2) patients diagnosed with primary progressive MS.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!